Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas. Show more

1901 West 47th Place, Kansas City, KS, 66205, United States

Biotechnology
Healthcare

Market Cap

60.67M

52 Wk Range

$3.20 - $11.89

Previous Close

$4.39

Open

$4.31

Volume

461,447

Day Range

$4.30 - $4.70

Enterprise Value

62.39M

Cash

10.95M

Avg Qtr Burn

-3.597M

Insider Ownership

30.97%

Institutional Own.

9.04%

Qtr Updated

12/31/25